Zhang N, Gordon ML (2018) <br />Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients<br /><i>Clin Interv Aging</i> <b>13</b>: 1963<br /><br />Homma A, Atarashi H, Kubota N, Nakai K, Takase T (2016) <br />Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial<br /><i>J Alzheimers Dis</i> <b>52</b>: 345<br /><br />Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003) <br />beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies<br /><i>Biochemical Pharmacology</i> <b>65</b>: 407<br /><br />Alagiakrishnan K, Wong W, Blanchette PL (2000) <br />Use of donepezil in elderly patients with Alzheimer's disease--a Hawaii based study<br /><i>Hawaii Med J</i> <b>59</b>: 57<br /><br />Camps P, Cusack B, Mallender WD, Achab RE, Morral J, Munoz-Torrero D, Rosenberry TL (2000) <br />Huprine X is a Novel High-Affinity Inhibitor of Acetylcholinesterase That Is of Interest for Treatment of Alzheimer's Disease<br /><i>Molecular Pharmacology</i> <b>57</b>: 409<br /><br />Cummings JL, Donohue JA, Brooks RL (2000) <br />The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease<br /><i>American Journal of Geriatry & Psychiatry</i> <b>8</b>: 134<br /><br />Jann MW (2000) <br />Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease<br /><i>Pharmacotherapy</i> <b>20</b>: 1<br /><br />Kaur J, Zhang MQ (2000) <br />Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors<br /><i>Curr Med Chem</i> <b>7</b>: 273<br /><br />Kosasa T, Kuriya Y, Matsui K, Yamanishi Y (2000) <br />Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats<br /><i>European Journal of Pharmacology</i> <b>389</b>: 173<br /><br />Ogura H, Kosasa T, Araki S, Yamanishi Y (2000) <br />[Pharmacological properties of donepezil hydrochloride (Aricept), a drug for Alzheimer's disease]<br /><i>Nihon Yakurigaku Zasshi</i> <b>115</b>: 45<br /><br />Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000) <br />Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats<br /><i>Methods Find Exp Clin Pharmacol</i> <b>22</b>: 89<br /><br />Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000) <br />Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro<br /><i>Methods Find Exp Clin Pharmacol</i> <b>22</b>: 609<br /><br />Sugimoto H, Iimura Y, Kawakami Y, Yamanishi Y (2000) <br />Donepezil Hydrochloride (E2020) and Other Acetylcholinesterase Inhibitors<br /><i>Curr Med Chem</i> <b>7</b>: 303<br /><br />Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetlik DA (2000) <br />Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients<br /><i>J Clin Psychiatry</i> <b>61</b>: 487<br /><br />Doody RS (1999) <br />Clinical profile of donepezil in the treatment of Alzheimer's disease<br /><i>Gerontology</i> <b>45</b>: 23<br /><br />Kryger G, Silman I, Sussman JL (1999) <br />Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs<br /><i>Structure</i> <b>7</b>: 297<br /><br />Lopez-Pousa S, Lombardia Fernandez C (1999) <br />[Treatment of Alzheimer's disease: acetylcholinesterase inhibitors].<br /><i>Neurologia</i> <b>14</b>: 180<br /><br />Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, Su XQ, Zhong XS, Cheng RY, Xu WA, Li JX, Feng B (1999) <br />Huperzine-A in capsules and tablets for treating patients with Alzheimer disease<br /><i>Zhongguo Yao Li Xue Bao</i> <b>20</b>: 486<br /><br />Barner EL, Gray SL (1998) <br />Donepezil use in Alzheimer disease<br /><i>Annals of Pharmacotherapy</i> <b>32</b>: 70<br /><br />Cheng DH, Tang XC (1998) <br />Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities<br /><i>Pharmacol Biochem Behav</i> <b>60</b>: 377<br /><br />Collier J (1998) <br />Drug and Therapeutics Bulletin defends its stance over donepezil [letter]<br /><i>British Medical Journal</i> <b>316</b>: 1092<br /><br />Costagli C, Galli A (1998) <br />Inhibition of cholinesterase-associated aryl acylamidase activity by anticholinesterase agents: focus on drugs potentially effective in Alzheimer's disease<br /><i>Biochemical Pharmacology</i> <b>55</b>: 1733<br /><br />Giacobini E (1998) <br />Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications<br /><i>Neurochem Int</i> <b>32</b>: 413<br /><br />Hasegawa K (1998) <br />How to cope with Alzheimer's disease?<br /><i>Neurobiology of Aging</i> <b>19</b>: S107<br /><br />Kryger G, Silman I, Sussman JL (1998) <br />Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica<br /><i>Journal de Physiologie Paris</i> <b>92</b>: 191<br /><br />Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1998) <br />Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group<br /><i>Archives of Internal Medicine</i> <b>158</b>: 1021<br /><br />Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) <br />A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group<br /><i>Neurology</i> <b>50</b>: 136<br /><br />Rogers SL, Friedhoff LT (1998) <br />Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study<br /><i>European Neuropsychopharmacology</i> <b>8</b>: 67<br /><br />Ross JS, Shua-Haim JR (1998) <br />Aricept-induced nightmares in Alzheimer's disease: 2 case reports [letter]<br /><i>J Am Geriatr Soc</i> <b>46</b>: 119<br /><br />Svensson AL, Nordberg A (1998) <br />Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells<br /><i>Neuroreport</i> <b>9</b>: 1519<br /><br />Taverni JP, Seliger G, Lichtman SW (1998) <br />Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation<br /><i>Brain Injury</i> <b>12</b>: 77<br /><br />Wang T, Tang XC (1998) <br />Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine<br /><i>European Journal of Pharmacology</i> <b>349</b>: 137<br /><br />Anderson R, Higgins GA (1997) <br />Absence of central cholinergic deficits in ApoE knockout mice<br /><i>Psychopharmacology (Berl)</i> <b>132</b>: 135<br /><br />Boothby H, Zaidi SM, Seth V, Khalaf S, Jameel H, Mahomed S, al Y (1997) <br />Advertisements for donepezil. National policy needs to be set for prescribing of this drug<br /><i>BMJ</i> <b>315</b>: 1624<br /><br />Bryson HM, Benfield P (1997) <br />Donepezil<br /><i>Drugs & Aging</i> <b>10</b>: 234<br /><br />Geldmacher DS (1997) <br />Donepezil (Aricept) therapy for Alzheimer's disease<br /><i>Compr Ther</i> <b>23</b>: 492<br /><br />Gray S (1997) <br />Advertisements for donepezil (Aricept) in the BMJ. Advertisement suggests an unrealistic improvement in mental status<br /><i>BMJ</i> <b>314</b>: 1555<br /><br />Jones RW, Mann JB, Saunders SA (1997) <br />Advertisements for donepezil. Prices charged for private prescriptions for donepezil show huge variation<br /><i>BMJ</i> <b>315</b>: 1624<br /><br />Kojima J, Nakajima K, Ochiai M, Nakayama K (1997) <br />Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia [published erratum appears in Methods Find Exp Clin Pharmacol 1997 Jun;19(5):364]<br /><i>Methods Find Exp Clin Pharmacol</i> <b>19</b>: 245<br /><br />McGuffey EC (1997) <br />Alzheimer's disease: an overview for the pharmacist<br /><i>J Am Pharm Assoc</i> <b>3</b>: 347<br /><br />Rupniak NM, Tye SJ, Field MJ (1997) <br />Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys<br /><i>Psychopharmacology</i> <b>131</b>: 406<br /><br />Tsukada H, Kakiuchi T, Ando I, Ouchi Y (1997) <br />Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: a positron emission tomography study in unanesthetized monkeys<br /><i>Journal of Pharmacology & Experimental Therapeutics</i> <b>281</b>: 1408<br /><br />Wagner N (1997) <br />Advertisements for donepezil (Aricept) in the BMJ. Local committee has declined to approve NHS hospital prescription of donepezil<br /><i>BMJ</i> <b>314</b>: 1555<br /><br />Whitehouse PJ, Juengst E, Mehlman M, Murray TH (1997) <br />Enhancing cognition in the intellectually intact<br /><i>Hastings Center Report</i> <b>27</b>: 14<br /><br />Wilkinson D (1997) <br />Advertisements for donepezil. Review of drug in Drug and Therapeutics Bulletin is uninformed<br /><i>BMJ</i> <b>315</b>: 1625<br /><br />Cheng DH, Ren H, Tang XC (1996) <br />Huperzine A, a novel promising acetylcholinesterase inhibitor<br /><i>Neuroreport</i> <b>8</b>: 97<br /><br />Inoue A, Kawai T, Wakita M, Iimura Y, Sugimoto H, Kawakami Y (1996) <br />The simulated binding of (+/-)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]m eth yl] -1H-inden-1-one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure-activity analyses<br /><i>Journal of Medicinal Chemistry</i> <b>39</b>: 4460<br /><br />Rogers SL, Friedhoff LT (1996) <br />The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo- Controlled Trial. The Donepezil Study Group<br /><i>Dementia</i> <b>7</b>: 293<br /><br />Matsui K, Oda Y, Ohe H, Tanaka S, Asakawa N (1995) <br />Direct determination of E2020 enantiomers in plasma by liquid chromatography-mass spectrometry and column-switching techniques<br /><i>Journal of Chromatography A</i> <b>694</b>: 209<br /><br />Nochi S, Asakawa N, Sato T (1995) <br />Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020)<br /><i>Biol Pharm Bull</i> <b>18</b>: 1145<br /><br />Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K (1995) <br />Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2- yl)methyl]piperidine hydrochloride and related compounds<br /><i>Journal of Medicinal Chemistry</i> <b>38</b>: 4821<br /><br />Galli A, Mori F, Benini L, Cacciarelli N (1994) <br />Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020<br /><i>European Journal of Pharmacology</i> <b>270</b>: 189<br /><br />Pang YP, Kozikowski AP (1994) <br />Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program<br /><i>J Comput Aided Mol Des</i> <b>8</b>: 683<br /><br />Dawson GR, Iversen SD (1993) <br />The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory<br /><i>Behavioural Brain Research</i> <b>57</b>: 143<br /><br />